Brief: Metacrine Initiates Phase 2a Trial Of MET642 For Treatment Of Patients With NASH
09/03/2021 11:39
March 9 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE INITIATES PHASE 2A TRIAL OF MET642 FOR THE
TREATMENT
OF PATIENTS WITH NASH
* METACRINE, INC. - TOPLINE TRIAL RESULTS OF UP TO 180
PATIENTS
ARE EXPECTED TO BE REPORTED IN FIRST HALF OF 2022
Source text for Eikon: ID:nGNXc6j7Fd
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions